Second-line treatment options in hepatocellular carcinoma

Drugs in Context

article

Donatella Marino¹  Clizia Zichi¹  Marco Audisio¹  Elisa Sperti²  Massimo Di Maio¹ 

[1] Department of Oncology, University of Turin;Division of Medical Oncology, Ordine Mauriziano Hospital

关键词: cabozantinib;    hepatocellular carcinoma;    immunotherapy;    ramucirumab;    regorafenib;    second line;    treatment.;   

DOI  :  10.7573/dic.212577

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

For many years, sorafenib has been the only approved systemictreatment for advanced hepatocellular carcinoma (HCC). Forover a decade, randomized controlled trials exploring theefficacy of new drugs both in first- and second-line treatmenthave failed to prove any survival benefit. However, in the pastfew years, several advances have been made especially inpretreated patients; phase III trials of regorafenib, cabozantinib,and ramucirumab in patients with elevated α-fetoprotein havedemonstrated efficacy in patients progressing after or intolerantto sorafenib. In addition, early phase I and II trials have shownpromising results of immunotherapy alone or in combinationwith tyrosine-kinase inhibitors or monoclonal antibodies inthe same setting of patients. In this review, we will discuss theevidence on second-line options for HCC, focusing on the latestresults that are currently refining the treatment scenario.

【 授权许可】

CC BY-NC-ND